TY - JOUR
T1 - The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer
AU - Gennari, A.
AU - Donati, S.
AU - Danesi, R.
AU - Fogli, S.
AU - Orlandini, C.
AU - Del Tacca, M.
AU - Conte, P. F.
PY - 2000
Y1 - 2000
N2 - The purpose of this study was to determine the response rate of the gemcitabine/epirubicin/paclitaxel combination (GET) and its feasibility as induction chemotherapy before high-dose consolidation treatment in patients with metastatic breast cancer. Patients received gemcitabine 1,000 mg/m2 on days 1 and 4, epirubicin 90 mg/m2 on day 1, and paclitaxel 175 mg/m2 on day 1 every 3 weeks for up to eight courses. After six courses of GET, responding patients or those with stable disease entered a high-dose chemotherapy program. All 36 enrolled patients were evaluated for toxicity and response. The GET combination was well tolerated, with myelosuppression the being most common toxicity; grade 4 neutropenia was reported in 56% of patients. The overall response rate was 89% (95% confidence interval, 73.4% to 96.9%), with a 28% complete response rate. The high-dose chemotherapy program resulted in a response rate of 92% and a complete response rate of 44%. As a result of the promising activity demonstrated in this phase II study with GET and following high-dose chemotherapy, three related studies are planned: an in vitro study evaluating the possible synergism of paclitaxel and gemcitabine, a phase III study comparing GET with epirubicin/paclitaxel in metastatic breast cancer, and a phase II trial evaluating GET in patients with operable breast cancer. Copyright (C) 2000 by W.B. Saunders Company.
AB - The purpose of this study was to determine the response rate of the gemcitabine/epirubicin/paclitaxel combination (GET) and its feasibility as induction chemotherapy before high-dose consolidation treatment in patients with metastatic breast cancer. Patients received gemcitabine 1,000 mg/m2 on days 1 and 4, epirubicin 90 mg/m2 on day 1, and paclitaxel 175 mg/m2 on day 1 every 3 weeks for up to eight courses. After six courses of GET, responding patients or those with stable disease entered a high-dose chemotherapy program. All 36 enrolled patients were evaluated for toxicity and response. The GET combination was well tolerated, with myelosuppression the being most common toxicity; grade 4 neutropenia was reported in 56% of patients. The overall response rate was 89% (95% confidence interval, 73.4% to 96.9%), with a 28% complete response rate. The high-dose chemotherapy program resulted in a response rate of 92% and a complete response rate of 44%. As a result of the promising activity demonstrated in this phase II study with GET and following high-dose chemotherapy, three related studies are planned: an in vitro study evaluating the possible synergism of paclitaxel and gemcitabine, a phase III study comparing GET with epirubicin/paclitaxel in metastatic breast cancer, and a phase II trial evaluating GET in patients with operable breast cancer. Copyright (C) 2000 by W.B. Saunders Company.
UR - http://www.scopus.com/inward/record.url?scp=0033975321&partnerID=8YFLogxK
M3 - Article
SN - 0093-7754
VL - 27
SP - 14
EP - 19
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 1 SUPPL. 1
ER -